JP2015500792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500792A5 JP2015500792A5 JP2014526308A JP2014526308A JP2015500792A5 JP 2015500792 A5 JP2015500792 A5 JP 2015500792A5 JP 2014526308 A JP2014526308 A JP 2014526308A JP 2014526308 A JP2014526308 A JP 2014526308A JP 2015500792 A5 JP2015500792 A5 JP 2015500792A5
- Authority
- JP
- Japan
- Prior art keywords
- clostridium
- bacterium
- lachnospiraceae bacterium
- composition according
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193403 Clostridium Species 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 241000193464 Clostridium sp. Species 0.000 claims 16
- 241000894006 Bacteria Species 0.000 claims 14
- 108020004414 DNA Proteins 0.000 claims 8
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 claims 8
- 210000003289 regulatory T cell Anatomy 0.000 claims 7
- 241000904817 Lachnospiraceae bacterium Species 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000428313 Anaerotruncus colihominis Species 0.000 claims 5
- 241001098250 [Clostridium] lavalense Species 0.000 claims 5
- 241000193450 [Clostridium] symbiosum Species 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 241000963043 Anaerostipes caccae DSM 14662 Species 0.000 claims 4
- 241000828262 Erysipelotrichaceae bacterium 2_2_44A Species 0.000 claims 4
- 241001531274 Faecalicatena contorta Species 0.000 claims 4
- 241001134569 Flavonifractor plautii Species 0.000 claims 4
- 241000263846 Lachnospiraceae bacterium 3_1_57FAA_CT1 Species 0.000 claims 4
- 241000263847 Lachnospiraceae bacterium 5_1_57FAA Species 0.000 claims 4
- 241000985249 [Clostridium] indolis Species 0.000 claims 4
- 241000685809 [Clostridium] saccharogumia Species 0.000 claims 4
- 241000371060 [Clostridium] saccharolyticum WM1 Species 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000005259 measurement Methods 0.000 claims 4
- 241001202853 Blautia Species 0.000 claims 3
- 241001674997 Hungatella hathewayi Species 0.000 claims 3
- 241000263845 Lachnospiraceae bacterium 6_1_63FAA Species 0.000 claims 3
- 241001464895 Lachnospiraceae bacterium DJF_VP30 Species 0.000 claims 3
- 241001042460 Oscillibacter valericigenes Species 0.000 claims 3
- 241000741965 [Clostridium] asparagiforme DSM 15981 Species 0.000 claims 3
- 241001147801 [Clostridium] scindens Species 0.000 claims 3
- 241001177797 [Clostridium] symbiosum WAL-14163 Species 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 241001505572 Anaerostipes caccae Species 0.000 claims 2
- 241000186063 Arthrobacter Species 0.000 claims 2
- 241000904825 Clostridiales bacterium Species 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000962959 Pseudoflavonifractor capillosus ATCC 29799 Species 0.000 claims 2
- 241000961103 [Clostridium] bolteae ATCC BAA-613 Species 0.000 claims 2
- 241001656794 [Clostridium] saccharolyticum Species 0.000 claims 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 2
- 229960004963 mesalazine Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- -1 oligofructose Chemical compound 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 244000144725 Amygdalus communis Species 0.000 claims 1
- 235000011437 Amygdalus communis Nutrition 0.000 claims 1
- 229920000945 Amylopectin Polymers 0.000 claims 1
- 241001013579 Anaerotruncus Species 0.000 claims 1
- 241000448677 Anaerotruncus colihominis DSM 17241 Species 0.000 claims 1
- 101100518558 Arabidopsis thaliana OTU9 gene Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 241001148536 Bacteroides sp. Species 0.000 claims 1
- 235000016068 Berberis vulgaris Nutrition 0.000 claims 1
- 241000335053 Beta vulgaris Species 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 229920002488 Hemicellulose Polymers 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 229920001202 Inulin Polymers 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 241001177766 Lachnospiraceae bacterium 2_1_46FAA Species 0.000 claims 1
- 241000928987 Lachnospiraceae bacterium A4 Species 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 241001515661 Oscillospiraceae bacterium NML 061048 Species 0.000 claims 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 1
- 229920000294 Resistant starch Polymers 0.000 claims 1
- 241000134861 Ruminococcus sp. Species 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 1
- 241001246487 [Clostridium] bolteae Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 235000020224 almond Nutrition 0.000 claims 1
- 230000002590 anti-leukotriene effect Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 229940041514 candida albicans extract Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229910052738 indium Inorganic materials 0.000 claims 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims 1
- 229940029339 inulin Drugs 0.000 claims 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 1
- 229960000511 lactulose Drugs 0.000 claims 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 235000013379 molasses Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 1
- 235000021254 resistant starch Nutrition 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000012138 yeast extract Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161565976P | 2011-12-01 | 2011-12-01 | |
| US61/565,976 | 2011-12-01 | ||
| US201261607360P | 2012-03-06 | 2012-03-06 | |
| US61/607,360 | 2012-03-06 | ||
| PCT/JP2012/007687 WO2013080561A1 (en) | 2011-12-01 | 2012-11-29 | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213526A Division JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500792A JP2015500792A (ja) | 2015-01-08 |
| JP2015500792A5 true JP2015500792A5 (enExample) | 2016-06-16 |
| JP6306507B2 JP6306507B2 (ja) | 2018-04-18 |
Family
ID=48535050
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014526308A Active JP6306507B2 (ja) | 2011-12-01 | 2012-11-29 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017213526A Active JP6492151B2 (ja) | 2011-12-01 | 2017-11-06 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2019038453A Active JP7097838B2 (ja) | 2011-12-01 | 2019-03-04 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2021005834A Active JP7165218B2 (ja) | 2011-12-01 | 2021-01-18 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2022168855A Active JP7503273B2 (ja) | 2011-12-01 | 2022-10-21 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
| JP2024087782A Pending JP2024129016A (ja) | 2011-12-01 | 2024-05-30 | 制御性ｔ細胞の増殖または集積を誘導するヒト由来細菌 |
Country Status (10)
| Country | Link |
|---|---|
| US (11) | US10238694B2 (enExample) |
| EP (4) | EP3569690B1 (enExample) |
| JP (6) | JP6306507B2 (enExample) |
| CN (3) | CN104160014A (enExample) |
| CA (1) | CA2892588A1 (enExample) |
| DK (2) | DK3978598T3 (enExample) |
| ES (2) | ES2994320T3 (enExample) |
| FI (2) | FI3569690T3 (enExample) |
| HK (1) | HK1204008A1 (enExample) |
| WO (1) | WO2013080561A1 (enExample) |
Families Citing this family (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| BR112013002667B1 (pt) | 2010-08-04 | 2020-02-04 | Thomas Julius Borody | composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las |
| JP5931884B2 (ja) | 2010-10-07 | 2016-06-08 | カリフォルニア インスティチュート オブ テクノロジー | 自閉症の生菌療法 |
| EP3610881A1 (en) | 2011-03-09 | 2020-02-19 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3569690B1 (en) | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| IN2014DN07752A (enExample) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| CA3008794C (en) | 2012-03-29 | 2021-03-16 | Therabiome, Llc | Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| US10220089B2 (en) | 2012-08-29 | 2019-03-05 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| CN104955466A (zh) | 2012-11-23 | 2015-09-30 | 赛里斯治疗公司 | 协同细菌组合物和其制造方法和用途 |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| WO2014121304A1 (en) | 2013-02-04 | 2014-08-07 | Seres Health, Inc. | Compositions and methods |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| EP3074027B1 (en) * | 2013-11-25 | 2024-12-18 | Seres Therapeutics, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| EP3082431A4 (en) * | 2013-12-16 | 2017-11-15 | Seres Therapeutics, Inc. | Bacterial compositions and methods of use thereof for treatment of immune system disorders |
| MX387331B (es) * | 2014-04-10 | 2025-03-18 | Riken | Composiciones y metodos para induccion de celulas th17. |
| US20150322176A1 (en) * | 2014-04-16 | 2015-11-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof |
| WO2015179437A1 (en) * | 2014-05-19 | 2015-11-26 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing clostridium difficile infection |
| HK1244461A1 (zh) | 2014-10-30 | 2018-08-10 | 加利福尼亚技术学院 | 用於改善神经发育障碍中的行为的包含细菌的组合物和方法 |
| EP3212207A4 (en) | 2014-10-30 | 2018-06-13 | California Institute of Technology | Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| MA41020A (fr) | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| DK3223835T3 (en) * | 2014-11-25 | 2025-02-17 | Memorial Sloan Kettering Cancer Center | Intestinal microbiota and gvhd |
| EP3193901B1 (en) | 2014-12-23 | 2018-04-04 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| ES2658310T3 (es) | 2014-12-23 | 2018-03-09 | 4D Pharma Research Limited | Una cepa de bacteroides thetaiotaomicron y su uso en la reducción de la inflamación |
| US20170360853A1 (en) * | 2015-01-07 | 2017-12-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies |
| CN107949391B (zh) | 2015-05-14 | 2021-11-09 | 克雷斯顿沃控股公司 | 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置 |
| PT3297644T (pt) | 2015-05-22 | 2022-03-30 | Univ Arizona State | Métodos para tratar distúrbios do espetro do autismo e sintomas associados |
| TWI759266B (zh) * | 2015-06-15 | 2022-04-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物之用途 |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA55434B1 (fr) | 2015-06-15 | 2022-02-28 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CN108135945A (zh) * | 2015-06-22 | 2018-06-08 | 哈佛大学校长及研究员协会 | 固有层调节性t细胞的诱导 |
| MX388995B (es) | 2015-06-25 | 2025-03-20 | Native Microbials Inc | Métodos, aparatos y sistemas para analizar cepas de microorganismos de comunidades heterogéneas complejas, predecir e indentificar sus relaciones funcionales e interacciones y seleccionar y sintetizar conjuntos microbianos basados en estos. |
| US9938558B2 (en) | 2015-06-25 | 2018-04-10 | Ascus Biosciences, Inc. | Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US10851399B2 (en) | 2015-06-25 | 2020-12-01 | Native Microbials, Inc. | Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon |
| US20190087536A1 (en) * | 2015-09-09 | 2019-03-21 | uBiome. Inc | Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues |
| CN115252650A (zh) | 2015-11-03 | 2022-11-01 | 布里格姆及妇女医院股份有限公司 | 用于治疗和/或预防食物变态反应的治疗性微生物群 |
| MA45287A (fr) | 2015-11-20 | 2018-08-22 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) * | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| EP4233884A3 (en) * | 2015-11-24 | 2023-10-04 | Seres Therapeutics, Inc. | Designed bacterial compositions |
| NZ743958A (en) | 2016-01-07 | 2023-07-28 | Native Microbials Inc | Methods for improving milk production by administration of microbial consortia |
| JP6675752B2 (ja) * | 2016-02-23 | 2020-04-01 | 国立大学法人佐賀大学 | 腸内Ｂｌａｕｔｉａ ｃｏｃｃｏｉｄｅｓ増殖刺激剤 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| PT3313423T (pt) | 2016-03-04 | 2019-07-10 | 4D Pharma Plc | Composições que compreendem a estirpe blautia bacteriana para tratar a hipersensibilidade visceral |
| AU2017234120B2 (en) | 2016-03-14 | 2024-06-20 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| WO2017160944A2 (en) | 2016-03-15 | 2017-09-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and preventing graft versus host disease |
| US11064722B2 (en) * | 2016-06-10 | 2021-07-20 | N.V. Nutricia | Risk of allergy and nutrition to reduce that risk |
| PT3468573T (pt) * | 2016-06-14 | 2023-10-16 | Vedanta Biosciences Inc | Tratamento de uma infeção por clostridium difficile |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10722600B2 (en) | 2016-06-17 | 2020-07-28 | New York University | Methods and compositions for treating cancer |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
| EP3518946A4 (en) | 2016-09-27 | 2020-09-09 | Board of Regents, The University of Texas System | METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| AU2017347870B2 (en) * | 2016-10-28 | 2024-05-23 | Vedanta Biosciences, Inc. | Methods and compositions for preserving bacteria |
| AU2017354716A1 (en) * | 2016-11-01 | 2019-05-02 | Keio University | Bacteria inducing Th1 cells |
| EP3541400B1 (en) * | 2016-11-18 | 2025-05-14 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018107365A1 (zh) * | 2016-12-13 | 2018-06-21 | 深圳华大基因研究院 | 粪厌氧棒杆菌(Anaerostipes caccae)及其应用 |
| CA3122548A1 (en) * | 2016-12-23 | 2018-06-28 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| AU2017386658A1 (en) | 2016-12-28 | 2019-07-25 | Native Microbials, Inc. | Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon |
| CN110352250A (zh) | 2016-12-28 | 2019-10-18 | 埃斯库斯生物科技股份公司 | 用于通过示踪剂分析法对复杂异质群落进行微生物株系分析、确定其功能关系及相互作用以及合成包括给药微生物群集和接种微生物群集的微生物群集的方法、设备和系统 |
| EP3579924A4 (en) * | 2017-02-07 | 2020-12-23 | California Institute of Technology | MODULATION OF THE INTESTINAL MICROBIOTE IN HUNTINGTON'S DISEASE AND RETT SYNDROME |
| US10596206B1 (en) | 2017-03-14 | 2020-03-24 | Cornell University | Probiotic compositions and methods of use |
| WO2018187272A1 (en) | 2017-04-03 | 2018-10-11 | Gusto Global, Llc | Rational design of microbial-based biotherapeutics |
| WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| WO2018187467A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
| WO2018201049A1 (en) | 2017-04-28 | 2018-11-01 | Ascus Biosciences, Inc. | Methods for supporting grain intensive and/or energy intensive diets in ruminants with a synthetic bioensemble of microbes |
| WO2018213262A1 (en) * | 2017-05-19 | 2018-11-22 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for reducing listeria monocytogenes infection or colonization |
| RS61872B1 (sr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| RS63393B1 (sr) | 2017-06-14 | 2022-08-31 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| GB201709763D0 (en) * | 2017-06-19 | 2017-08-02 | Probi Ab | Biological materials and methods |
| WO2019028402A1 (en) * | 2017-08-04 | 2019-02-07 | Second Genome, Inc. | ROSEBURIA HOMINIS, EUBACTERIUM ELIGENS AND COMBINATIONS THEREOF AS BIOTHERAPEUTIC AGENTS |
| EP3665181A4 (en) * | 2017-08-07 | 2021-06-09 | Finch Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| BR112020002992A2 (pt) | 2017-08-14 | 2020-08-18 | Seres Therapeutics, Inc. | composições e métodos para tratamento de doença colestática |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019046646A1 (en) | 2017-08-30 | 2019-03-07 | Whole Biome Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS |
| CA3080586A1 (en) | 2017-10-30 | 2019-05-09 | Seres Therapeutics, Inc. | Compositions and methods for treating antibiotic resistance |
| EP3476396A1 (en) * | 2017-10-31 | 2019-05-01 | Institut Gustave Roussy | Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same |
| JP7293220B2 (ja) * | 2017-11-09 | 2023-06-19 | ヴェダンタ バイオサイエンシーズ インコーポレーテッド | アレルギーの処置のための組成物および方法 |
| US10507221B2 (en) | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
| EP4410954A3 (en) * | 2017-12-11 | 2025-01-15 | Vedanta Biosciences, Inc. | Compositions and methods for suppressing pathogenic organisms |
| US20200368293A1 (en) * | 2018-01-18 | 2020-11-26 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of cancer |
| CN111886333A (zh) | 2018-02-09 | 2020-11-03 | 学校法人庆应义塾 | 诱导cd8+t细胞的组合物和方法 |
| CA3103385A1 (en) | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
| EP3594321A1 (en) * | 2018-07-10 | 2020-01-15 | Université catholique de Louvain | Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| CN113164526A (zh) | 2018-07-19 | 2021-07-23 | 潘德勒姆治疗公司 | 用于微生物植入的方法和组合物 |
| DE102018213030A1 (de) * | 2018-08-03 | 2020-02-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlung von Immunerkrankungen durch die antikörpervermittelte Neutralisierung spezifischer Darmbakterien |
| US12161680B2 (en) | 2018-08-17 | 2024-12-10 | Vedanta Biosciences, Inc. | Methods of decreasing dysbiosis and restoring a microbiome |
| CN113164527A (zh) | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| JP7444459B2 (ja) * | 2018-10-04 | 2024-03-06 | 国立研究開発法人理化学研究所 | ＩＬＣ２を標的としたＩｇＡ産生誘導方法 |
| WO2020097077A1 (en) * | 2018-11-05 | 2020-05-14 | The University Of Chicago | Methods and compositions for treating infectious, autoimmune, and allergic disease |
| WO2020234746A1 (en) | 2019-05-18 | 2020-11-26 | Janssen Biotech, Inc. | Materials and methods for microbiome modulation |
| CN114258299A (zh) * | 2019-07-17 | 2022-03-29 | 犹他大学研究基金会 | 梭菌纲聚生体组合物以及治疗肥胖症、代谢综合征和肠易激疾病的方法 |
| PE20221399A1 (es) | 2019-07-19 | 2022-09-15 | Finch Therapeutics Holdings Llc | Metodos y productos para el tratamiento de trastornos gastrointestinales |
| CN114502720A (zh) * | 2019-08-14 | 2022-05-13 | 瓦格宁根大学 | 包含myo-肌醇至丙酸途径的细菌 |
| US20230057586A1 (en) | 2019-08-16 | 2023-02-23 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| US20250270498A1 (en) * | 2019-08-16 | 2025-08-28 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| US20220282206A1 (en) | 2019-08-16 | 2022-09-08 | Janssen Biotech, Inc. | Optimized culture media for clostridia bacteria |
| JP2021045097A (ja) * | 2019-09-20 | 2021-03-25 | 腸内フローラ移植臨床研究株式会社 | 腸内フローラの健康状態の診断方法及びその利用 |
| CN115243697A (zh) * | 2019-11-22 | 2022-10-25 | 未知君有限责任公司 | 包含细菌物种的组合物及其相关方法 |
| US20230131960A1 (en) * | 2020-03-25 | 2023-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New strategy to treat and prevent diseases caused by enterobacteriae |
| EP3895710A1 (en) | 2020-04-15 | 2021-10-20 | DSM IP Assets B.V. | Food and/or feed compositions to manage immune homeostasis |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| WO2021234650A1 (en) * | 2020-05-21 | 2021-11-25 | Superbrewed Food, Inc. | Method of treating or preventing an infection |
| US12011467B2 (en) | 2021-05-18 | 2024-06-18 | J. Craig Venter Institute, Inc. | Bacterial formulation |
| CN116195742B (zh) * | 2021-11-30 | 2024-07-09 | 内蒙古伊利实业集团股份有限公司 | 乳双歧杆菌bl-99在保护软骨中的应用 |
| US20250025545A1 (en) * | 2021-12-02 | 2025-01-23 | Kanagawa Institute Of Industrial Science And Technology | Establishment of therapy and diagnosis for allergic diseases through control of immunoglobulin-binding protein |
| CN119970806A (zh) * | 2025-02-25 | 2025-05-13 | 浙江大学 | 多毛假解黄酮菌在制备预防、治疗和/或改善溃疡性结肠炎的药物中的应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3069074D1 (en) | 1979-11-16 | 1984-10-04 | Sterosynt Ltd | 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them |
| US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| US5599795A (en) | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US5700787A (en) | 1994-09-02 | 1997-12-23 | Brigham & Women's Hospital, Inc. | Capsular polysaccharide immunomodulator |
| US6368586B1 (en) | 1996-01-26 | 2002-04-09 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| JP4282763B2 (ja) | 1996-03-20 | 2009-06-24 | ザ、ユニバーシティ、オブ、ニュー、サウス、ウェイルズ | 消化管内の微生物個体数の変更 |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| JP2001112485A (ja) | 1999-10-19 | 2001-04-24 | Yakult Honsha Co Ltd | 腸内細菌用プライマー及び該プライマーを用いた検出方法 |
| FR2808689B1 (fr) | 2000-05-11 | 2004-09-03 | Agronomique Inst Nat Rech | Utilisation de souches acetogenes hydrogenotrophes pour la prevention ou le traitement de troubles digestifs |
| US20040170617A1 (en) | 2000-06-05 | 2004-09-02 | Finegold Sydney M. | Method of treating diseases associated with abnormal gastrointestinal flora |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| SV2003000753A (es) | 2000-12-05 | 2003-06-16 | Brigham & Womens Hospital | Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico |
| US7094555B2 (en) | 2001-04-05 | 2006-08-22 | Benaroya Research Institute At Virginia Mason | Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment |
| PE20030283A1 (es) | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0220809D0 (en) * | 2002-09-06 | 2002-10-16 | Univ College Of London | Immune modulator |
| GB0307026D0 (en) | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
| AU2004227852B2 (en) | 2003-03-31 | 2010-01-14 | The Brigham And Women's Hospital, Inc. | Zwitterionic immunomodulators for the treatment of asthma and allergy |
| WO2004104175A2 (en) | 2003-05-14 | 2004-12-02 | University Of Georgia Research Foundation, Inc. | Probiotic bacteria and methods |
| JP2005124495A (ja) | 2003-10-24 | 2005-05-19 | Yakult Honsha Co Ltd | ヒト腸内細菌検出用プライマー |
| EP1749538A4 (en) | 2004-03-31 | 2009-11-11 | Kirin Pharma Kk | METHOD FOR DETERMINING THE DIFFERENTIATION OF REGULATORY T CELLS AND THEIR PROLIFERATION WITH GPI ANCHOR PROTEIN AGONISTS AND MEDICINAL COMPOSITION THEREFOR |
| US8092793B2 (en) | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
| KR101260533B1 (ko) | 2005-03-03 | 2013-05-06 | 가부시키가이샤 메이지 | 면역기능 조정제 |
| CU23581A1 (es) * | 2005-10-28 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer |
| US8206726B2 (en) | 2006-02-06 | 2012-06-26 | The Brigham And Women's Hospital, Inc. | Zwitterionic polysaccharides for promotion of immune system maturation and health |
| DE102006062250A1 (de) | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden |
| ES2399993T3 (es) | 2007-03-02 | 2013-04-04 | Protectimmun Gmbh | Composición farmacéutica para la protección frente a alergias y enfermedades inflamatorias |
| EP1974743A1 (en) | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics to Improve Gut Microbiota |
| CN101310730A (zh) | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | 酪酸梭菌在制备防治类风湿性关节炎、强直性脊柱炎微生物制剂中的应用 |
| JP2009084215A (ja) | 2007-09-28 | 2009-04-23 | Nippon Paper Chemicals Co Ltd | 炎症性腸疾患予防・治療剤 |
| WO2009050486A2 (en) | 2007-10-19 | 2009-04-23 | The University Of Surrey | Peptide manipulators of regulatory t cell activity |
| JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
| CN101496819A (zh) | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
| KR100913405B1 (ko) | 2008-03-25 | 2009-08-21 | 광주과학기술원 | Ｔｈ２－매개 면역 질환의 예방 또는 치료용 조성물 |
| US8586029B2 (en) | 2008-06-04 | 2013-11-19 | Trustees Of Dartmouth College | Prevention or treatment of immune-relevant disease by modification of microfloral populations |
| JP2010129134A (ja) | 2008-11-28 | 2010-06-10 | Pulstec Industrial Co Ltd | ホログラム記録装置及びホログラム再生装置 |
| CN104655828B (zh) | 2009-02-13 | 2018-04-27 | 加州大学评议会 | 基于组织的诊断的系统、方法和装置 |
| GB0903016D0 (en) | 2009-02-23 | 2009-04-08 | Univ Gent | Method for alleviating intestinal problems and novel bacterial strains therefor |
| US20100275282A1 (en) | 2009-04-23 | 2010-10-28 | Round June L | Methods and systems for identifying immunomodulatory substances |
| US20100311686A1 (en) | 2009-06-03 | 2010-12-09 | Kasper Lloyd H | Nutraceutical composition and methods for preventing or treating multiple sclerosis |
| WO2011005756A1 (en) | 2009-07-06 | 2011-01-13 | Puretech Ventures, Llc | Delivery of agents targeted to microbiota niches |
| WO2011022542A2 (en) | 2009-08-19 | 2011-02-24 | Puretech Ventures, Llc | Administration of factors normally present in a microbial niche to improve health |
| WO2011022660A1 (en) | 2009-08-21 | 2011-02-24 | Puretech Ventures, Llc | Methods of diagnosing and treating microbiome-associated disease using interaction network parameters |
| WO2011027956A2 (ko) | 2009-09-04 | 2011-03-10 | 주식회사이언메딕스 | 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델 |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| AU2010317423C1 (en) | 2009-11-11 | 2015-01-22 | Alimentary Health Limited | A bifidobacterium strain |
| WO2011099514A1 (ja) * | 2010-02-10 | 2011-08-18 | 日環科学株式会社 | 好熱性微生物を用いた混合物、溶解液、及び医薬品 |
| WO2011151941A1 (ja) | 2010-06-04 | 2011-12-08 | 国立大学法人東京大学 | 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物 |
| US20120020941A1 (en) | 2010-07-26 | 2012-01-26 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| WO2012013861A2 (en) | 2010-07-26 | 2012-02-02 | Suomen Punainen Risti Veripalvelu | Use of blood group status iii |
| ES2388662B1 (es) | 2010-11-10 | 2014-04-11 | Consejo Superior De Investigaciones Científicas (Csic) | Nuevas cepas de duganella aisladas de la rizosfera de olivo silvestre y cultivado y su uso en la producción de violaceína. |
| US20120279149A1 (en) * | 2011-05-04 | 2012-11-08 | Sebastian George Quinn | System and device for utilization of energy in buildings |
| US20140171339A1 (en) * | 2011-06-06 | 2014-06-19 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting adenomas, colorectal cancer, and uses thereof |
| CA2848762C (en) | 2011-09-14 | 2021-07-27 | Queen's University At Kingston | Method for treatment of disorders of the gastrointestinal system |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP3569690B1 (en) * | 2011-12-01 | 2024-08-28 | The University of Tokyo | Human-derived bacteria that induce proliferation or accumulation of regulatory t cells |
| US8906668B2 (en) | 2012-11-23 | 2014-12-09 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
| KR20150103012A (ko) | 2012-11-26 | 2015-09-09 | 토마스 줄리어스 보로디 | 분변 마이크로바이오타 복원을 위한 조성물 및 이의 제조 및 사용 방법 |
| KR102222273B1 (ko) | 2013-02-04 | 2021-03-08 | 세레스 테라퓨틱스, 인코포레이티드 | 조성물 및 방법 |
| RU2015140610A (ru) | 2013-03-14 | 2017-04-17 | ТЕРАБАЙОМ, ЭлЭлСи | Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств |
| HK1220495A1 (zh) | 2013-03-14 | 2017-05-05 | Seres Therapeutics, Inc. | 从材料和组合物中检测和富集病原体的方法 |
| WO2014145958A2 (en) | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
| US9764019B2 (en) * | 2013-07-09 | 2017-09-19 | Vedanta Biosciences, Inc. | Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease |
| MX387331B (es) * | 2014-04-10 | 2025-03-18 | Riken | Composiciones y metodos para induccion de celulas th17. |
| EP3162150B1 (en) | 2014-06-27 | 2018-09-12 | Telefonaktiebolaget LM Ericsson (publ) | Network node and method for supporting time-sensitive services in a communication network |
| JP6671360B2 (ja) | 2014-06-30 | 2020-03-25 | サリックス ファーマスーティカルズ，インコーポレーテッド | 過敏性腸症候群（ｉｂｓ）を再治療するための方法 |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| WO2016194427A1 (ja) | 2015-05-30 | 2016-12-08 | 日環科学株式会社 | プロバイオティクス、あるいはプレバイオティクス、並びにその製造方法、微生物製剤、健康食品並びに医薬品 |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| US9642281B1 (en) * | 2015-12-28 | 2017-05-02 | Martas Precision Slide Co., Ltd. | Buckle set for sliding rail of industrial rackmount chassis |
| AU2017234120B2 (en) * | 2016-03-14 | 2024-06-20 | Holobiome, Inc. | Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system |
| US20170290889A1 (en) | 2016-04-11 | 2017-10-12 | New York University | Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders |
| JP6792103B2 (ja) | 2016-06-01 | 2020-11-25 | 株式会社テックコーポレーション | 微細気泡水供給システム |
| US9999641B2 (en) | 2016-06-14 | 2018-06-19 | Vedanta Biosciences, Inc. | Treatment of clostridium difficile infection |
| AU2017354716A1 (en) | 2016-11-01 | 2019-05-02 | Keio University | Bacteria inducing Th1 cells |
| CA3122548A1 (en) * | 2016-12-23 | 2018-06-28 | Keio University | Compositions and methods for the induction of cd8+ t-cells |
| EP3665181A4 (en) | 2017-08-07 | 2021-06-09 | Finch Therapeutics, Inc. | COMPOSITIONS AND PROCEDURES FOR DECOLONIZATION OF ANTIBIOTIC-RESISTANT BACTERIA IN THE INTESTINAL |
| JP2019046634A (ja) * | 2017-08-31 | 2019-03-22 | パナソニックＩｐマネジメント株式会社 | 照明システム及びコントローラ |
| US10507221B2 (en) * | 2017-11-09 | 2019-12-17 | Vedanta Biosciences, Inc. | Compositions and methods for the treatment of allergy |
-
2012
- 2012-11-29 EP EP19178787.8A patent/EP3569690B1/en active Active
- 2012-11-29 EP EP24196410.5A patent/EP4477750A3/en active Pending
- 2012-11-29 US US14/362,097 patent/US10238694B2/en active Active
- 2012-11-29 CN CN201280068081.8A patent/CN104160014A/zh active Pending
- 2012-11-29 CA CA2892588A patent/CA2892588A1/en active Pending
- 2012-11-29 FI FIEP19178787.8T patent/FI3569690T3/fi active
- 2012-11-29 JP JP2014526308A patent/JP6306507B2/ja active Active
- 2012-11-29 DK DK21198256.6T patent/DK3978598T3/da active
- 2012-11-29 CN CN201810228890.XA patent/CN108676774B/zh active Active
- 2012-11-29 DK DK19178787.8T patent/DK3569690T3/da active
- 2012-11-29 EP EP12854485.5A patent/EP2785828B1/en active Active
- 2012-11-29 WO PCT/JP2012/007687 patent/WO2013080561A1/en not_active Ceased
- 2012-11-29 CN CN202310526067.8A patent/CN116942833A/zh active Pending
- 2012-11-29 ES ES19178787T patent/ES2994320T3/es active Active
- 2012-11-29 FI FIEP21198256.6T patent/FI3978598T3/fi active
- 2012-11-29 HK HK15104633.8A patent/HK1204008A1/xx unknown
- 2012-11-29 EP EP21198256.6A patent/EP3978598B1/en active Active
- 2012-11-29 ES ES21198256T patent/ES2993669T3/es active Active
-
2016
- 2016-02-09 US US15/019,101 patent/US9649345B2/en active Active
- 2016-02-09 US US15/019,068 patent/US9642881B2/en active Active
-
2017
- 2017-03-28 US US15/471,493 patent/US10052353B2/en active Active
- 2017-04-14 US US15/487,553 patent/US10058578B2/en active Active
- 2017-11-06 JP JP2017213526A patent/JP6492151B2/ja active Active
-
2018
- 2018-04-27 US US15/964,285 patent/US10183045B2/en active Active
- 2018-10-15 US US16/160,004 patent/US10342832B2/en active Active
- 2018-10-25 US US16/170,344 patent/US10835559B2/en active Active
-
2019
- 2019-03-04 JP JP2019038453A patent/JP7097838B2/ja active Active
- 2019-05-31 US US16/427,899 patent/US10624933B2/en active Active
-
2020
- 2020-10-15 US US17/071,425 patent/US11547732B2/en active Active
-
2021
- 2021-01-18 JP JP2021005834A patent/JP7165218B2/ja active Active
-
2022
- 2022-10-21 JP JP2022168855A patent/JP7503273B2/ja active Active
- 2022-12-20 US US18/068,725 patent/US20240000858A1/en active Pending
-
2024
- 2024-05-30 JP JP2024087782A patent/JP2024129016A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500792A5 (enExample) | ||
| Demopoulos et al. | Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials | |
| JP2018039833A5 (enExample) | ||
| US20250367242A1 (en) | Designed bacterial compositions and uses thereof | |
| Loretelli et al. | PD-1 blockade counteracts post–COVID-19 immune abnormalities and stimulates the anti–SARS-CoV-2 immune response | |
| FI3978598T3 (fi) | Ihmisperäisiä bakteereja, jotka indusoivat regulatoristen t-solujen proliferaatiota tai kertymistä | |
| JP2021078504A5 (enExample) | ||
| Boutin et al. | Bacterial–fungal interactions in the neonatal gut influence asthma outcomes later in life | |
| Patel et al. | Is prevention the best treatment? CMV after lung transplantation | |
| US12427175B2 (en) | Fecal fungome and therapeutic efficacy of fecal microbiota transplantation | |
| Kanter et al. | Cytomegalovirus infection renal transplant recipients: risk factors and outcome | |
| Hill et al. | A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus | |
| Eksteen | Advances and controversies in the pathogenesis and management of primary sclerosing cholangitis. | |
| Rittà et al. | Everolimus-based immunosuppressive regimens in lung transplant recipients: impact on CMV infection | |
| Lehto et al. | Human herpesvirus-6 and-7 after lung and heart–lung transplantation | |
| Yamani et al. | The impact of CytoGam on cardiac transplant recipients with moderate hypogammaglobulinemia: a randomized single-center study | |
| JP2016065039A5 (enExample) | ||
| Gerna et al. | Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients | |
| Kır et al. | Impact of prophylaxis vs pre-emptive approach for cytomegalovirus infection in kidney transplant recipients | |
| Durante-Mangoni et al. | Effect of the immunosuppressive regimen on the incidence of cytomegalovirus infection in 378 heart transplant recipients: a single centre, prospective cohort study | |
| Piñana et al. | Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC) | |
| Nijskens et al. | Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: Clinical relevance and impact on patient morbidity | |
| Galarraga et al. | Influence of ganciclovir prophylaxis on citomegalovirus, human herpesvirus 6, and human herpesvirus 7 viremia in renal transplant recipients | |
| Marques et al. | Cryptococcosis in renal transplant recipients: a single-center experience | |
| Singh et al. | Indoleamine-2, 3-dioxygenase inhibition improves immunity and is safe for concurrent use with cART during Mtb/SIV coinfection |